109,596 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Purchased by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 109,596 shares of the medical research company's stock, valued at approximately $57,107,000.

Other hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Thermo Fisher Scientific by 1.7% in the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after purchasing an additional 127,564 shares during the period. Coldstream Capital Management Inc. grew its stake in shares of Thermo Fisher Scientific by 11.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after buying an additional 995 shares during the last quarter. Greenwood Gearhart Inc. raised its stake in Thermo Fisher Scientific by 9.8% during the third quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock valued at $12,730,000 after buying an additional 1,837 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after acquiring an additional 10,606 shares in the last quarter. Finally, S.E.E.D. Planning Group LLC increased its holdings in shares of Thermo Fisher Scientific by 6.2% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock valued at $5,528,000 after acquiring an additional 618 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Remove Ads

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 in the last quarter. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on TMO. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Bank of America reduced their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a report on Friday, December 13th. Sanford C. Bernstein raised Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. Finally, Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $647.09.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded down $32.75 during mid-day trading on Thursday, reaching $420.80. The company's stock had a trading volume of 1,620,223 shares, compared to its average volume of 1,681,716. The stock has a fifty day moving average of $516.75 and a two-hundred day moving average of $541.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 52 week low of $409.85 and a 52 week high of $627.88. The firm has a market capitalization of $158.75 billion, a PE ratio of 25.45, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific's payout ratio is currently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.